Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Beijing Doing Biomedical
- 04 Feb 2018 Planned End Date changed from 1 Jun 2020 to 1 Sep 2020.
- 04 Feb 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.
- 04 Feb 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.